Article Versions Notes

Houmsse M, Muskara A, Pasca D, Roy A, Sughra S, Ghazi S, Addison D, Husain M. Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review. Cancers. 2025; 17(5):827. https://doi.org/10.3390/cancers17050827

Houmsse, Mustafa, Andrew Muskara, Damaris Pasca, Arnab Roy, Sana Sughra, Sanam Ghazi, Daniel Addison, and Marium Husain. 2025. "Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review" Cancers 17, no. 5: 827. https://doi.org/10.3390/cancers17050827

Houmsse, M., Muskara, A., Pasca, D., Roy, A., Sughra, S., Ghazi, S., Addison, D., & Husain, M. (2025). Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review. Cancers, 17(5), 827. https://doi.org/10.3390/cancers17050827